Objective-Stem cell therapy for angiogenesis and vascular regeneration has been investigated using adult or embryonic stem cells. In the present study, we investigated the potential of endothelial cells (ECs) derived from human induced pluripotent stem cells (hiPSCs) to promote the perfusion of ischemic tissue in a murine model of peripheral arterial disease. Methods and Results-Endothelial differentiation was initiated by culturing hiPSCs for 14 days in differentiation media supplemented with BMP-4 and vascular endothelial growth factor. The hiPSC-ECs exhibited endothelial characteristics by forming capillary-like structures in matrigel and incorporating acetylated-LDL. They stained positively for EC markers such as KDR, CD31, CD144, and eNOS. In vitro exposure of hiPSC-ECs to hypoxia resulted in increased expression of various angiogenic related cytokines and growth factors. hiPSC-ECs were stably transduced with a double fusion construct encoded by the ubiquitin promoter, firefly luciferase for bioluminescence imaging and green fluorescence protein for fluorescent detection. The hiPSC-ECs (5ϫ10 5 ) were delivered by intramuscular injection into the ischemic hindlimb of SCID mice at day 0 and again on day 7 after femoral artery ligation (nϭ8). Bioluminescence imaging showed that hiPSC-ECs survived in the ischemic limb for at least 2 weeks. In addition, laser Doppler imaging showed that the ratio of blood perfusion was increased by hiPSC-EC treatment by comparison to the saline-treated group (0.58Ϯ0.12 versus 0.44Ϯ0.04; Pϭ0.005). The total number of capillaries in the ischemic limb of mice receiving hiPSC-EC injections was greater than those in the saline-treated group (1284Ϯ155 versus 797Ϯ206 capillaries/mm 2 ) (PϽ0.002). 
S tem cell therapy for angiogenesis and vascular regeneration has been investigated previously using diverse cell types, including adult mesenchymal stem cells, endothelial progenitor cells, embryonic stem cells (ESCs), and recently with human induced pluripotent stem cells (hiPSCs). [1] [2] [3] [4] [5] The hiPSCs share many similar characteristics with human ESCs. In addition to having similar capacity for self-renewal, they are capable of differentiating into cells of all three germ layers. However, unlike hESCs, hiPSCs are derived from reprogramming of somatic cells and therefore represent a source of autologous pluripotent stem cells that may obviate the immunologic concerns of hESCs. Furthermore, hiPSCs can be experimentally derived from easily accessible and plentiful human tissue sources such as skin or fat. Consequently, hiPSCs provide a suitable platform for modeling diseases in vitro and also serve as a potential source of cells for regenerative medicine.
Previously, hiPSCs have been shown to differentiate into endothelial cells (ECs). 6 However, the therapeutic potential of hiPSC-derived ECs (hiPSC-ECs) for the treatment of ischemic diseases has not been reported. In this study, we describe the differentiation of hiPSCs into ECs and characterize their histological and functional properties in vitro. In
The human induced pluripotential stem cells (hiPSCs) were derived from human foreskin fibroblasts using retroviral constructs encoding the Yamanaka factors as previously described. 7 Their complete characterization is described elsewhere (B. Byers, unpublished data, 2010); but in addition, we performed alkaline phosphatase staining, immunohistochemistry for pluripotency markers, and teratoma assay (see supplemental files available online at http://atvb.ahajournals.org). To initiate differentiation, confluent cultures of hiPSCs were transferred to ultra-low attachment dishes containing differentiation media for 4 days to form embryoid bodies. The 4-day embryoid bodies were then seeded on 0.2% gelatin-coated dishes and cultured for another 10 days in differentiation media. To purify the hiPSC-ECs, we incubated single cell suspensions with PE-conjugated anti-human CD31 antibody (Ab). Flow cytometry was then performed to obtain purified hiPSC-ECs.
Characterization of hiPSC-ECs
The hiPSC-ECs were stained with Abs against endothelial markers such as PECAM-1, vascular endothelial-cadherin, endothelial nitric oxide synthase, and von Willebrand factor (vWF). Uptake of acetylated LDL was assessed by incubating the cells with Dil-labeled ac-LDL. For the tube formation assay, cells were seeded on 24-well plates precoated with growth factor-reduced Matrigel and incubated for 24 hours. Human antibody arrays were used to assess the various cytokines secreted by the hiPSC-ECs in normoxic and hypoxic conditions.
In Vivo Studies
For in vivo Matrigel injection, Matrigel was mixed with bFGF and hiPSC-ECs (5ϫ10 5 ). The mixture was subcutaneously injected into SCID mice. After 14 days, the Matrigel plugs were removed, paraffin-embedded, sectioned, and stained with CD31 Ab.
For non-invasive tracking in vivo, the hiPSC-ECs and fibroblasts were transduced with a lentiviral vector carrying an ubiquitin promoter driving firefly luciferase and enhanced green fluorescence protein as described previously. 9
The Therapeutic Effects of hiPSC-ECs Were Studied In Ischemic Tissue
Hindlimb ischemia was induced by ligating the femoral artery of male NOD SCID mice. 10 The animals were assigned to receive intramuscular injection into the gastrocnemius muscle of either saline, hiPSC-ECs, or human fibroblasts. On subsequent days, animals were injected with D-luciferin, and bioluminescence imaging (BLI) was performed to assess cell survival and location. 11 Perfusion of the ischemic and nonischemic hindlimb was assessed using laser Doppler spectroscopy. At the end of the study period, the gastrocnemius tissue was harvested, snap frozen in O.C.T. compound for cryosectioning, and stained using a mouse-specific CD31. Capillary density was assessed by counting the number of capillaries in 5 high-powered fields in each of 4 tissue sections and expressing the data as capillaries/mm 2 . 11 Survival of transplanted cells was visualized by staining with a vWF Ab that reacts with both murine and human capillaries. The hiPSC-ECs were detected by their coexpression of GFP and vWF. The transplanted cells were also detected using a human specific vascular endothelial-cadherin Ab.
All animal studies were approved by our Administrative Panel on Laboratory Animal Care.
Results

Characterization of HUF5 iPSC Line
The hiPSC line was generated by retrovirus-mediated transduction of optimal cutting temperature-4, Sox-2, Klf-4, and c-Myc using primary human adult dermal fibroblasts obtained from a healthy 46-year old female. The hiPSC colonies expressed pluripotency markers such as SSEA3/4, TRA-1 to -81, TRA-I-60, Nanog and alkaline phosphatase (Supplemental Figure IA , available online at http://atvb.ahajournals.org) and formed teratomas in vivo (Supplemental Figure IB) .
Isolation and Characterization of hiPSC-ECs
The hiPSC-ECs were isolated by fluorescent activated cell sorting after 2 weeks of differentiation and then expanded for further characterization. The typical yield of ECs generated from the HUF5 hiPSC line ranged between 5% to 20% ( Figure 1A ). The expanded hiPSC-ECs formed a "cobblestone" monolayer, and immunofluorescence staining revealed that these cells were positive for endothelial markers such as CD31, CD144, endothelial nitric oxide synthase, and vWF ( Figure 1B-1E ). In addition, they were able to incorporate acetylated LDL and form networks of tubular structures after 24 hours of culture on matrigel ( Figure 1F -G). Furthermore, when hiPSC-ECs were placed in matrigel, and injected subcutaneously in immunodeficient mice, they formed capillaries ( Figure 1H ). These capillaries were continuous with the murine systemic circulation as they contained blood cells (Insert, Figure 1H ).
Derivation and Characterization of Transduced hiPSC-ECs
The hiPSC-ECs were stably transduced with the double fusion reporter construct (Supplemental Figure II , available online at http://atvb.ahajournals.org) and fluorescent activated cell sorting sorted for dual expression of GFP and CD31. Less than 20% of the hiPSC-ECs expressed both GFP and CD31 after transduction; but after several passages, about 75% were GFP and CD31 positive before cell transplantation ( Figure 2A ). They maintained the cobblestone morphology in culture and manifested mRNA and protein expression of CD31 and CD34 ( Figure 2B-D) . There was a strong correlation between the Fluc activity and cell number (R 2 ϭ0.99; Figure 2E ).
Survival of hiPSC-ECs in the Ischemic Hindlimb
In initial studies, we injected single dosages of 5ϫ10 5 hiPSCECs to the ischemic hindlimb only on day 0 and tracked the survival of the cells over 14 days. We observed a decline in BLI that became undetectable by day 11 ((Supplemental Figure IX , available online at http://atvb.ahajournals.org). For this reason, for the remainder of the studies, we administered cells on day 0 as well as day 7.
Upon transplantation into the ischemic limb, the hiPSCECs could be detected in the ischemic limb noninvasively by BLI (Figure 3 ). After each of the injections on day 0 and on Arterioscler Thromb Vasc Biol November 2011 day 7, there was an increase in bioluminescence intensity, followed by a gradual decrease over several days ( Figure 3B ). Additional experiments were carried out in which ischemic hindlimbs of SCID mice were injected on days 0 and 7 with human fibroblasts that were transduced by the same lentiviral vector for Fluc expression. As shown in Supplemental Figure  III (available online at http://atvb.ahajournals.org), the fibroblast bioluminescence also correlated strongly with cell number. Like hiPSC-ECs, there was a decline in bioluminescence signal during the first 4 days, followed by an increase after the second dose of cell injection on day 7, and then a gradual decrease with time. In contrast to hiPSC-ECs, the fibroblasts were detected for up to 4 weeks in the ischemic limb (Supplemental Figure IV -VI, available online at http://atvb.ahajournals.org).
Improvement of Blood Perfusion in Ischemic Hindlimbs by hiPSC-EC Transplantation
Laser Doppler perfusion imaging was performed to determine the effects of localized transplantation of hiPSC-EC on the ischemic hindlimb at days 0, 4, 7, and 14 post-treatment. The hindlimb perfusion ratio (ischemic/control hindlimb) was significantly improved in the hiPSC-EC treated mice by comparison to the saline-treated mice (Pϭ0.005; Figure 4A-B) .
To assess the survival and effect of hiPSC-ECs with a longer time course, and in comparison to treatment with fibroblasts, additional experiments were carried out to 4 weeks postinjection. The cells in this experiment were not transduced with Fluc to preclude the possible effects of lentiviral vectors on cell behavior. As shown in Supplemental Figure VI , the mean perfusion ratio of the hiPSC-EC-treated group (0.53Ϯ0.10) was significantly greater after 4 weeks, than that of the saline-or fibroblast-treated groups (0.37Ϯ0.04 and 0.42Ϯ0.07; Pϭ0.009 and Pϭ0.003, respectively). This data suggests that hiPSC-ECs were therapeutic cells that enhanced limb perfusion for up to 4 weeks postdelivery.
Improved Blood Capillary Density on hiPSC-EC Transplantation
To verify the laser Doppler data, we quantified capillary density by immunofluorescence staining. Murine capillary density in the 2-week cell-treated group was greater than that of the saline-treated group (Figure 5A-B) . Dual staining for both GFP and vWF demonstrated the persistence of hiPSCECs in the ischemic limb at low frequency ( Figure 6A ). Human-derived vascular endothelial-cadherin positive cells in capillaries were also occasionally observed in the tissue Figure VII , available online at http://atvb.ahajournals.org). These results suggest that the therapeutic effect of hiPSC-ECs may be related to its ability to incorporate into and/or enhance expansion of the endogenous microvasculature.
sections (Supplemental
Angiogenic Cytokines Secreted by the Transplanted hiPSC-ECs in the Ischemic Hindlimbs
To further understand the mechanism by which hiPSC-ECs enhanced angiogenesis in the ischemic limbs, we assessed the cells in vitro for the expression of angiogenic cytokines under hypoxic and normoxic conditions. Indeed, hiPSC-ECs expressed a majority of the angiogenic cytokines, in some cases at higher levels of expression than primary HMDECs. These cytokines include Angiopoietin-1, vascular endothelial growth factor-A and -C, and platelet-derived growth factor-AA ( Figure 6B) . The results for the entire angiogenic protein array of 55 cytokines and growth factors are shown in Supplemental Figure VIII (available online at http://atvb.ahajournals.org). This upregulation of angiogenic cytokines by the hiPSC-ECs in hypoxia is consistent with the enhanced blood perfusion and capillary density in the ischemic limbs that received hiPSC-ECs.
Discussion
Somatic cells may be reprogrammed into iPSCs using induced expression of transcriptional factors involved in maintaining pluripotency. 7, 12 Expression of optimal cutting temperature-3/4, Sox2, Klf4, and c-Myc in somatic cells reprograms these cells as evidenced by the relengthening of the telomeres 13, 14 and the acquisition of pluripotency similar to that of embryonic stem cells. 15 Thus, hiPSCs represent a promising cell source for regenerative medicine. These cells are particularly attractive because they can be used to generate patient specific pluripotent cells that do not face an immunologic barrier. However, the therapeutic potential of hiPSCs remains largely untested. Recently, hiPSC-derived neurons, cardiomyocytes, and mesenchymal stem cells have shown therapeutic promise in preclinical studies. 16 -18 The present study is the first to assess the potential of hiPSCderived endothelial cells for ischemic vascular disease. We find that hiPSCs can be differentiated into ECs as indicated by typical cobblestone monolayer morphology, expression of EC surface markers and cytoplasmic factors, and manifestation of characteristic endothelial functions (acetylated LDL uptake and capillary-like network formation in matrigel).
When these cells were delivered to the ischemic limb of the mouse by intramuscular injection, they increased capillary density and limb perfusion. In contrast, injection of fibroblasts did not improve limb perfusion by comparison to vehicle. We observed some hiPSC-ECs that appeared to incorporate into the microvasculature and others that were in 
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close proximity. However, the observed increase in capillary density could not be accounted for simply by the incorporation of hiPSC-EC into the existing vasculature. Instead, it is likely that the injected cells had a paracrine effect. Indeed, we find that the hiPSC-ECs secrete angiogenic cytokines and growth factors in the presence of hypoxia, as well or better than primary human endothelial cells. One concern in using iPSC-derived cells is the possibility of contamination of the therapeutic cells with parental iPSCs, which could lead to teratoma formation. We did not observe any tumor formation in any of our animals receiving hiPSCECs. However, longer term studies with greater numbers of mice, and/or more sensitive probes to detect undifferentiated cells, are necessary to provide greater assurance that the differentiation process is complete. Also, further study is needed to resolve concerns regarding the possible adverse effects of abnormal imprinting, copy number variation, or other somatic mutations arising from the reprogramming or differentiation process.
Using molecular imaging, we observed a reduction in cell number over time in the ischemic limb. Bioluminescence imaging is a sensitive and accurate method for tracking cells in vivo with as few as 500 cells. 9 We found that the number of transplanted cells began to decrease within 24 hours post-transplantation. In order to improve the efficacy of our hiPSC-EC transplantation, we did a second injection at day 7 postsurgery. The transplanted cells face the serious challenge of an unfriendly environment characterized by reduced oxygen and nutrient supply and the presence of various cytotoxic and inflammatory products in the ischemic limb. In addition, although we are using an immunodeficient mouse model, the human cells may stimulate a mild immune reaction and/or may not be receiving appropriate signaling required for their efficient integration into the mouse vasculature.
Adult stem cells (such as those derived from the bone marrow, circulating mononuclear cells, or mesenchymal stem cells) have been used in small clinical trials of patients with myocardial ischemia or peripheral arterial disease. 19 -24 Only a few of these trials have been randomized, with large enough numbers of subjects, followed for sufficient period of time, to draw conclusions. These early data have shown proof of concept that cell therapy can provide some benefit in the setting of ischemic syndromes. However, adult stem cells such as endothelial progenitor cells have limited replicative capacity, and are few in number and dysfunctional, in elderly patients with cardiovascular risk factors. [25] [26] [27] By contrast hESCs have unlimited capacity to replicate, can be differentiated into ECs, and in preclinical studies have shown beneficial effects in the setting of myocardial or limb ischemia. 28 -34 Previously we have observed that ESC-derived ECs can home to sites of peripheral ischemia, incorporate into the microvasculature, increase capillary density, and improve limb perfusion. However, there is an immunogenic barrier for ESC-derivatives and this can pose a challenge in clinical application. By contrast, hiPSCs can be used to generate autologous therapies, minimizing or eliminating the need for immune suppression after cell transplantation. However, before hiPSCs can be considered for clinical applications, a number of technical issues need to be addressed. Currently most hiPSCs are generated using integrating viral vectors. 7, 12 However, integration of foreign DNA could inadvertently silence indispensable genes, or generate an oncogenic phenotype. Thus, clinical grade therapeutic cells might be derived using nonintegrating episomal vector systems, 35 cell permeant peptides, 36,37 RNA 38 and/or small molecules 39 or RNA-based approaches. 40 In addition, the efficiency and speed of hiPSC generation should be increased, and the fidelity of reprogramming (as assessed by epigenetic, genomic, proteomic, and functional studies) must be assured. In this regard, we and others note heterogeneity between hiPSC clones in differentiation potential. These differences are more exaggerated in hiPSC as compared to hESC clones. 41 The reasons for the reduced tendency to differentiate down some lineages in some hiPSC lines are not fully known but may include factors such as persistent "epigenetic memory" as recently described. 42, 43 Differentiation to functional lineages must be assured, and the risk reduced of transplanting pluripotential or suboptimally differentiated cells. Finally, it is unclear how iPSC-ECs compare in therapeutic efficacy to other clinically relevant cell types such as bone marrow mononuclear cells, endothelial progenitor cells, and mesenchymal stem cells, which each enhance blood flow recovery and improve angiogenesis in the murine hindlimb ischemia model 44 -52 (Supplemental Table I ).
In conclusion, this is the first study to demonstrate that functional human ECs may be differentiated from hiPSCs, as evidenced by in vitro characterization and in vivo application in a murine model of peripheral arterial disease. This is another step forward toward developing hiPSC-derived cell therapy for vascular regeneration.
